AZD2936

Phase 2Biologic

AstraZeneca

AZD2936 is one of 97 biologic programs targeting Non-Small Cell Lung Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CarcinomaActive, not recruiting

Advanced or Metastatic NSCLCActive, not recruiting

Molecular Residual DiseaseRecruiting

CancerActive, not recruiting

Non-Small Cell Lung CarcinomaPreclinical

Active, not recruiting

Advanced or Metastatic NSCLCPhase 1

Active, not recruiting

Molecular Residual DiseasePhase 2

Recruiting

CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

57 competitors in Cancer

#DrugCompanyPhaseTrials

Vemlidy

Gilead

Approved

1 2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 3

Tecentriq

Roche

Phase 2

5 4

Keytruda

Merck & Co.

Phase 2

4 5

Cotellic

Roche

Phase 2

3 6

Afinitor

Novartis

Phase 2

3 7

Erivedge

Roche

Phase 2

2 8

Verzenio

Eli Lilly

Phase 2

2 9

Stivarga

Bayer

Phase 2

2 10

Imfinzi

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Advanced or Metastatic NSCLC

NCT04612751

Q2 2028

PreclinicalActive, not recruiting

Non-Small Cell Lung Carcinoma

NCT04995523

Q3 2028

Phase 2Recruiting

Molecular Residual Disease

NCT05414032

Clinical

Trials by Indication[1]

Cancer1 trial

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT03819465·175 enrolled

Molecular Residual Disease1 trial

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT05414032·102 enrolled

Advanced or Metastatic NSCLC1 trial

A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT04612751·155 enrolled

Non-Small Cell Lung Carcinoma1 trial

Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT04995523·212 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AZD2936. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD2936 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD2936. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD2936

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q3 2028

Trials by Indication[1]

Cancer1 trial

Molecular Residual Disease1 trial

Advanced or Metastatic NSCLC1 trial

Non-Small Cell Lung Carcinoma1 trial

References

Drug Info

Quick Facts

Related News